GYRE THERAPEUTICS, INC. (GYRE) SEC Filings & Earnings Calls

No material risk signals; routine executive change filing.

GAAP loss per share; Etorel and Contiva sales declining; acquisition integration risk.

“GAAP basic EPS: $(0.12); Etorel sales down 81% YoY; Contiva sales down 40% YoY.”

China regulatory and procurement risk

“lower Contiva TM and Etorel TM product revenues following the implementation of China's national centralized procurement program.” · word for word

Integration risk from Cullgen acquisition

“Transaction costs of $6.9 million incurred in H1 2026 related to Cullgen acquisition and termination of prior merger.”

Foreign exchange risk

“Other expense, net increased by $0.5 million, or 176%, primarily due to higher foreign currency exchange loss.” · word for word

Dependence on China regulatory and commercial environment

“Gyre Pharmaceuticals is subject to restrictions on foreign exchange and cross-border cash transfers, including to parent companies and U.S. stockholders.” · word for word

Significant increase in operating expenses

“Total operating expenses increased 61% to $31.9M from $19.8M.”

Hydronidone approval and commercial launch risk

“The NDA submission is subject to initial formatting and completeness verification, and the Company plans to work with the CDE to submit any supplementary materials.”

Core product ETUARY sales declining 3% YoY; reliance on new product launches for growth.

“ETUARY sales $21.0M vs $21.7M.”

Operating loss widening due to transaction costs and increased R&D/SG&A; path to profitability uncertain.

“Operating loss -$9.4M vs income +$2.3M; R&D +118%.”

Integration risk from Cullgen acquisition; pipeline prioritization may delay programs.

“Comprehensive evaluation of pipeline and clinical development strategy underway.”

Concentrated ownership and control risk

“Aggregate amount beneficially owned by each reporting person 86,323,015.00 ... Percent of class represented by amount in Row (11) 69.1 %” · word for word

China regulatory risk

“Applicable PRC laws and regulations may be tightened, and new laws or regulations may be introduced to impose additional government approval, license, and permit requirements.” · word for word

Dilution risk

“Total Series B Preferred Stock 3,697,236 ... Common stock (as converted) 18,486,180” · word for word

Merger closing risk

“The consummation of the Merger is subject to certain closing conditions, including... approval by the requisite Cullgen stockholders... and a filing under the HSR Act.” · word for word

Regulatory approval risk for Hydronidone NDA

“We currently expect to submit an NDA seeking conditional approval in the first half of 2026, subject to completion of regulatory and technical preparations.” · word for word

BIOSECURE Act supply chain risk

“In light of the legislation commonly referred to as the BIOSECURE Act... we are actively monitoring potential implications for our manufacturing and supply chain arrangements.” · word for word

Competition in MASH

“Resmetirom... became the first drug to be approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis”

FY2026 revenue guidance decline from FY2025 actual ($100.5-111.0M vs $116.6M) indicates potential headwinds from generic competition or market dynamics.

“Full year 2026 revenue guidance of $100.5 to $111.0 million” · word for word

Acquisition integration risk for Cullgen ($300M stock transaction) and reliance on regulatory approvals for Hydronidone.

“Entered into agreement to acquire Cullgen... transaction anticipated to close in the second quarter of 2026” · word for word

Revenue guidance cut due to delayed Etorel rollout and government procurement uncertainty in China.

“Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to delayed Etorel® (Nintedanib) rollout and government procurement-related uncertainty.” · word for word

U.S. MASH IND delayed to 2026, indicating potential regulatory or data-readiness challenges.

“U.S. MASH IND anticipated timeline adjusted to 2026 to allow for incorporation of complete Phase 2 and 3 data and planning of hepatic impairment study.”